1. Clarke JTR. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ. 2006;174(2):189–90.
2. Standing Committee on Health. Prescription drugs part 1 – common drug review: an F/P/T process. Ottawa: Parliament of Canada; 2007. Available from: http://www.parl.gc.ca/HousePublications/Publication.aspx?DocId=3162492&Language=E&Mode=1&Parl=39&Ses=2 . Accessed 20 Mar 2017.
3. Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases – a case study in oncology. Can J Clin Pharmacol. 2009;16(2):e282–4.
4. Weeks C. Canada lags behind on rare disease drugs. Globe & Mail 2014 Feb 27. Available from: http://www.theglobeandmail.com/life/health-and-fitness/health/canada-lags-behind-on-rare-disease-drugs/article17137268 . Accessed 20 Mar 2017.
5. Feltmate K, Janiszewski PM, Gingerich S, Cloutier M. Delayed access to treatments for rare diseases: who’s to blame? Respirology. 2015;20(3):361–9.